Neurol. praxi. 2020;21(5):380-383 | DOI: 10.36290/neu.2020.078

Multiple sclerosis: adherence to treatment

MUDr. Zbyšek Pavelek, Ph.D., MUDr. Simona Halúsková, MUDr. Jana Šarláková, prof. MUDr. Martin Vališ, Ph.D.
Neurologická klinika LF a FN Hradec Králové

Multiple sclerosis is a chronic inflammatory autoimmune disease which affect central nervous system. Treatment initiation of early multiple sclerosis may postpone the development of disease progression and disablement. Adherence to treatment fundamentally contributes to achieving optimal results of therapy, improving the quality of life of patients and reducing healthcare costs.

Keywords: multiple sclerosis, adherence, treatment.

Received: June 9, 2020; Revised: June 24, 2020; Accepted: June 25, 2020; Prepublished online: June 25, 2020; Published: November 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Halúsková S, Šarláková J, Vališ M. Multiple sclerosis: adherence to treatment. Neurol. praxi. 2020;21(5):380-383. doi: 10.36290/neu.2020.078.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bertoli D, Serana F, Sottini A, et al. Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position - 174 of the IL-6 Promoter Gene. PLoS One 2015; 10(8): e0135441. Go to original source... Go to PubMed...
    2. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83(11): 1022-1024. Go to original source... Go to PubMed...
    3. Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data. J Neurosci Nurs 2010; 42(Suppl. 5): S5-S9. Go to original source... Go to PubMed...
    4. Cook S, Leist T, Comi G , Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Must Scler Relat Disord 2019; 29: 157-167. Go to original source... Go to PubMed...
    5. Crawford A, Jewell S, Mara H, McCatty L, Pelfrey R. Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Prefer Adherence 2014; 8: 1093-1099. Go to original source... Go to PubMed...
    6. De Ceuninck Van Capelle A, Van Der Meide H, Vosman FJH, Visser LH. A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS). PLoS One 2017; 12(8): e0182806. Go to original source... Go to PubMed...
    7. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2010; 18(1): 69-77. Go to original source... Go to PubMed...
    8. Dionne C, Ganguly R, Camac A, Chaves C. Do oral disease modifying agents (DMTs) improve adherence to MS treatment? A comparison of oral and injectable drugs. Presented at: Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); May 27-30; 2015; Indianapolis, IN, USA.
    9. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004; 36(3): 120-129. Go to original source... Go to PubMed...
    10. Gudesblatt M, Gorbatsevych O, Bumstead B, Zarif M, Thippeswarmy G, Thotam S, Fafard L, Buhse M. Natalizumab: real life adherence to disease modifying therapy in multiple sclerosis care. ECTRIMS Online Library. Gudesblatt M. 10/04/13; 34525; P1045.
    11. Hauser SL, Bar-Or A, Comi G Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3): 221-234. Go to original source... Go to PubMed...
    12. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O'Leary M, Smith-Williamson L. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabil Nurs 2001; 26(5): 172-176. Go to original source... Go to PubMed...
    13. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. J Manag Care Spec Pharm 2017; 23(8): 844-852. Go to original source... Go to PubMed...
    14. Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long term experience and an update on the clinical evidence. Ther Adv Neurol Disord 2016; 9(2): 130-147. Go to original source... Go to PubMed...
    15. Kolb-Mäurer A, Goebeler M, Mäurer M. Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis. Int J Mol Sci 2015; 16(7): 14951-14960. Go to original source... Go to PubMed...
    16. Kozma CM, Phillips AL, Meletiche DM. Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis. J Manag Care Spec Pharm. 2014;2 0(8): 800-807. Go to original source... Go to PubMed...
    17. Loonstra FC, van Rossum JA, van Kempen ZL, Rispens T, Uitdehaag BM, Killestein J. Infusion-related events during natalizumab: No need for post-infusion monitoring. Mult Scler 2019; 1352458519860415. Go to original source... Go to PubMed...
    18. Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT; RIVER study group. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv 2016; 13(7): 931-935. Go to original source... Go to PubMed...
    19. Munsell M, Locklear JC, Phillips AL, Frean M, Menzin J. An assessment of adherence among multiple sclerosis patients newly initiating treatment with a self-injectable versus oral disease-modifying drug. Presented at: Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); May 27-30; 2015; Indianapolis, IN, USA. Go to original source...
    20. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900. Go to original source... Go to PubMed...
    21. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303. Go to original source... Go to PubMed...
    22. Phillips JT, Erwin AA, Agrella S, Kremenchutzky M, Kramer JF, Darkes MJM, Kendter K, Abourjaily H, Rana J, Fox RJ. Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. Nerol Ther 2015; 4(2): 137-146. Go to original source... Go to PubMed...
    23. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag 2016; 12: 339-350. Go to original source... Go to PubMed...
    24. Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 2011; 24(3): 230-237. Go to original source... Go to PubMed...
    25. Sabate E, ed. Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003. [cit. 2020-05-18]. Dostupný: https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf?sequence=1&isAllowed=y.
    26. Shah S, Cooperman T, Kachur S. Evaluation of treatment adherence and persistence based on dosing frequency and route for self-administration of disease-modifying therapies in multiple sclerosis. Presented at: Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting; April 7-10; 2015; San Diego, CA, USA.
    27. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs 2010; 70(13): 1677-1691. Go to original source... Go to PubMed...
    28. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010; 30(2): 89-100. Go to original source...
    29. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011; 28(1): 51-61. Go to original source...
    30. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008; 255(Suppl. 1): 37-43. Go to original source...
    31. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009; 256(4): 568-576. Go to original source...
    32. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007; 13(9): 1146-1152. Go to original source... Go to PubMed...
    33. Vališ M, Šarláková J, Halúsková S, Klímová B, Potužník P, Peterka M, Kuča K, Štourač P, Mareš J, Pavelek Z. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®. Expert Opin Drug Deliv 2020; 17(5): 719-724. Go to original source...
    34. Van Reenen E, Van Der Borg W, Visse M, Van Der Meide H, Visser L. Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication. Int J Qual Stud Health Well-being 2019; 14(1): 1648946. Go to original source... Go to PubMed...
    35. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos LK, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014; 20: 705-716. Go to original source... Go to PubMed...
    36. Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Mult Scler Relat Disord 2020; 39: 101929. Go to original source... Go to PubMed...
    37. Vytřísalová M. Adherence k medikamentózní léčbě - známá neznámá [online]. Remedia 2009, 3 [cit. 2020-05-18]. Dostupný: http://www.remedia.cz/Clanky/Prehledy-nazory-diskuse/Adherence-k-medikamentozni-lecbe-znama-neznama/6-F-Gb.magarticle.aspx.
    38. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relasing multiple sclerosis. BMJ 2016; 354: i3518. Go to original source...
    39. Wynn DR. Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Mult Scler Int 2019; 2019: 7151685. Go to original source... Go to PubMed...
    40. Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017; 10(10): 343-359. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.